Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours
S Ezziddin, F Khalaf, M Vanezi, T Haslerud… - European journal of …, 2014 - Springer
Purpose The clinical benefit of peptide receptor radionuclide therapy (PRRT) in patients with
pancreatic neuroendocrine tumours (pNET) has not yet been well described and defined in …
pancreatic neuroendocrine tumours (pNET) has not yet been well described and defined in …
Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours
A Sabet, T Haslerud, UF Pape, A Sabet… - European journal of …, 2014 - Springer
… Torjan Haslerud … Amir Sabet, Torjan Haslerud, Amin Sabet, Hojjat Ahmadzadehfar,
Stefan Guhlke, Hans-Jürgen Biersack & Samer Ezziddin … Torjan Haslerud …
Stefan Guhlke, Hans-Jürgen Biersack & Samer Ezziddin … Torjan Haslerud …
Specific efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced neuroendocrine tumours of the small intestine
A Sabet, K Dautzenberg, T Haslerud, A Aouf… - European journal of …, 2015 - Springer
Purpose Increasing evidence supports the value of peptide receptor radionuclide therapy (PRRT)
in patients with metastatic neuroendocrine tumours (NET), but there are limited data …
in patients with metastatic neuroendocrine tumours (NET), but there are limited data …
Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate
…, K Ezziddin, UF Pape, K Reichman, T Haslerud… - European journal of …, 2014 - Springer
Purpose Renal radiation during peptide receptor radionuclide therapy (PRRT) may result in
glomerular damage, a potential reduction of glomerular filtration rate (GFR) and ultimately …
glomerular damage, a potential reduction of glomerular filtration rate (GFR) and ultimately …
F18-FDG-PET for recurrent differentiated thyroid cancer: a systematic meta-analysis
T Haslerud, K Brauckhoff, L Reisæter… - Acta …, 2016 - journals.sagepub.com
Background Positron emission tomography (PET) with fluor-18-deoxy-glucose (FDG) is widely
used for diagnosing recurrent or metastatic disease in patients with differentiated thyroid …
used for diagnosing recurrent or metastatic disease in patients with differentiated thyroid …
90Y Radioembolization after radiation exposure from peptide receptor radionuclide therapy
…, C Meyer, S Kahancova, T Haslerud… - Journal of Nuclear …, 2012 - Soc Nuclear Med
Previous radiation therapy of the liver is a contraindication for performing 90 Y microsphere
radioembolization, and its safety after internal radiation exposure through peptide receptor …
radioembolization, and its safety after internal radiation exposure through peptide receptor …
The significance of bremsstrahlung SPECT/CT after yttrium-90 radioembolization treatment in the prediction of extrahepatic side effects
…, K Wilhelm, C Kuhl, K Biermann, T Haslerud… - European journal of …, 2012 - Springer
Purpose Unwanted deposition of 90 Y microspheres in organs other than the liver during
radioembolization of liver tumours may cause severe side effects such as duodenal ulcer. The …
radioembolization of liver tumours may cause severe side effects such as duodenal ulcer. The …
[HTML][HTML] Phase II study of everolimus and temozolomide as first-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms
…, JB Svensson, EM Tabaksblat, TM Haslerud… - British journal of …, 2023 - nature.com
Background The optimal treatment for metastatic high-grade gastroenteropancreatic (GEP)
neuroendocrine neoplasms when Ki-67 ≤55% is unknown. A prospective multi-centre phase …
neuroendocrine neoplasms when Ki-67 ≤55% is unknown. A prospective multi-centre phase …
[HTML][HTML] A phase I prospective, non-randomized trial of autologous dendritic cell-based cryoimmunotherapy in patients with metastatic castration-resistant prostate …
…, SH Kaada, GK Melve, TM Haslerud… - Cancer Immunology …, 2023 - Springer
Metastatic castration-resistant prostate cancer (mCRPC) is an immunologically cold disease
with dismal outcomes. Cryoablation destroys cancer tissue, releases tumor-associated …
with dismal outcomes. Cryoablation destroys cancer tissue, releases tumor-associated …
Significance of oral administration of sodium perchlorate in planning liver-directed radioembolization
…, H Ahmadzadehfar, M Muckle, T Haslerud… - Journal of Nuclear …, 2011 - Soc Nuclear Med
99m Tc-macroaggregated albumin ( 99m Tc-MAA) scanning precedes radioembolization of
the liver to detect extrahepatic shunting to the lung or gastrointestinal tract. Despite strict …
the liver to detect extrahepatic shunting to the lung or gastrointestinal tract. Despite strict …